Last reviewed · How we verify

NCT04142333: GIA

GIA in Cascade Testing

Status unknown NA Last updated 3 November 2022
What this trial tests

NA trial testing GIA in Genetic Predisposition in 20 participants. Status unknown.

Timeline
18 December 2020
Primary endpoint
9 August 2021
1 December 2022

Quick facts

Lead sponsorUniversity of Virginia
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment20
Start date18 December 2020
Primary completion9 August 2021
Estimated completion1 December 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Virginia

Who can join

18 and older, female only, with Genetic Predisposition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this pilot study is to evaluate the feasibility and acceptability of GIA in sharing genetic test results with family members. To determine the utility of GIA in sharing information. To determine the impact of GIA on downstream cascade testing rates.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Genetic Predisposition

Currently open trials in the same condition.

Other University of Virginia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04142333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing